Please login to the form below

Moderna Therapeutics

This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... Moderna’s mRNA technology attempts to turn a patient’s own

Latest news

Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... Today brings the latest confirmation of that, with Merck &Co expanding its existing collaboration with Moderna Therapeutics to develop and
BMS to explore new options for its immuno-oncology drug Opdivo

The company will work with PsiOxus Therapeutics to evaluate the safety and efficacy of the Oxford, UK biotech's enadenotucirev in combination with Opdivo for the treatment of a range of ... Like BMS, Merck &Co has also moved to extend the reach of its
Merck & Co signs cancer vaccines research deal for Keytruda

The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke
mRNA - message received

Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical
AZ and Redx collaborate on genetics of cancer

Research will take place at Alderley Park site

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new drug
Deal Watch June 2016

Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.
Deal Watch October 2015

Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
Deal Watch table for January 2014

300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
Deal Watch table for October 2013

Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Tony de Fougerolles joins Evox Therapeutics as CEO

Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Medicxi appoints former GSK chair Moncef Slaoui

Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
MIT chief financial officer joins Moderna Therapeutics

US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
PureTech Health appoints chief scientific officer

Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
Dr Michael Watson appointed as president of Valera

Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president. ... Moderna's technology, coupled with its goal to deliver transformative

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Lead Copywriter: Competitive

Healthcare Senior Account Manager: Competitive

PMHub

Add my company

Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...